ReviewPharmaceutics2022
Application of Nanomaterials in the Prevention, Detection, and Treatment of Methicillin-Resistant
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Local anesthetics as a tool for Staphylococcus spp. control: a systematic review.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Pooled it
- Antibacterial Activity of α-Sulfamidophosphonate Derivatives and Their In Silico Assessment as Dihydropteroate Synthase Binders.Chemistry & biodiversity · 2026Article
- Computational screening of antimicrobial peptide analogs targeting AdeB efflux transporter protein in Acinetobacter baumannii associated with multidrug resistance.Scientific reports · 2026Article
- Nanoparticle carriers in the treatment of intracellular bacterial infections: Current approaches and challenges.International journal of pharmaceutics: X · 2026Review
- Advances in phytochemical-derived nanotherapeutics for multimodal eradication of multidrug-resistantFrontiers in pharmacology · 2026Review
- PLGA Nanoparticles Double-Decorated with a TAT Peptide and Folic Acid to TargetInternational journal of molecular sciences · 2025Article
- Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Harnessing Ultrasonic Technologies to TreatMolecules (Basel, Switzerland) · 2025Review
- Nanomedicine in the Fight Against Multidrug-Resistant Infections: A Review on Emerging Strategies and Translational Prospects.International journal of nanomedicine · 2025Review
- Staphylococcal Drug Resistance: Mechanisms, Therapies, and Nanoparticle Interventions.Infection and drug resistance · 2025Review
- Green carbon dots in the era of AI: sustainable synthesis, intelligent drug delivery, advanced diagnostics, and bioimaging.Turkish journal of biology = Turk biyoloji dergisi · 2025Review
- Vancomycin-Loaded Isogenous Membrane Vesicles for Macrophage Activation and Intracellular Methicillin-ResistantInternational journal of nanomedicine · 2025Article
- The application of CRISPR-Cas system inHeliyon · 2024Article
- Review
- A systematic overview of metal nanoparticles as alternative disinfectants for emerging SARS-CoV-2 variants.Archives of microbiology · 2024Review
- Fighting Methicillin-ResistantInternational journal of molecular sciences · 2023Review
- Review
- Nickel Nanoparticles: Applications and Antimicrobial Role against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2022Review
- Intracellular Habitation ofBiomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to differences in geographic surveillance systems, chemical sanitization practices, and antibiotic stewardship (AS) implementation employed during the COVID-19 pandemic, many experts have expressed concerns regarding a future surge in global antimicrobial resistance (AMR). A potential beneficiary of these differences is the Gram-positive bacteria MRSA. MRSA is a bacterial pathogen with a high potential for mutational resistance, allowing it to engage various AMR mechanisms circumventing conventional antibiotic therapies and the host's immune response. Coupled with a lack of novel FDA-approved antibiotics reaching the clinic, the onus is on researchers to develop alternative treatment tools to mitigate against an increase in pathogenic resistance. Mitigation strategies can take the form of synthetic or biomimetic nanomaterials/vesicles employed in vaccines, rapid diagnostics, antibiotic delivery, and nanotherapeutics. This review seeks to discuss the current potential of the aforementioned nanomaterials in detecting and treating MRSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.